The malignant lymphomas are a heterogeneous group of blood cancers that have distinctive biologic features and overlapping clinical presentations. All are associated with important risks of morbidity and mortality, and yet all also have well-developed treatment pathways that offer therapeutic benefit, including curative potentials. Systemic therapies, including immunotherapies, together with the judicious use of radiotherapy are the mainstays of treatment. For some groups, autologous hematopoietic cell transplant (HCT) offers curative or highly valuable palliative potential when there is progressive lymphoma after initial therapy.1 Allogeneic HCT may offer curative potential for patients who have progressive lymphoma after receiving these treatments.2 The primary mechanism of action leading to benefit from allogeneic HCT is through immunologic pathways associated with graft-vs-lymphoma effects.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Berg T, Mian HS, Meyer RM. Registry Data and Conditioning Therapy for Allogeneic Hematopoietic Cell Transplant and Lymphoma. JAMA Oncol. 2020;6(7):989–991. doi:10.1001/jamaoncol.2020.1303
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: